Compounds and compositions useful for treating disorders related to NTRK

1. A method for treating a subject suffering from a tumor by inhibiting neurotrophic tyrosine receptor kinase (NTRK) activity, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein:

Ring A is cycloalkyl or heterocyclyl;

each R A is independently selected from monocyclic or bicyclic aryl, monocyclic or bicyclic heteroaryl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic heterocyclyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, halo, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 heteroalkyl, —N(R 1 )(R 1 ), cyano, —C(O)R 1 , —OC(O)R 1 , —C(O)OR 1 , —SR 1 , —S(O) 2 R 1 , —S(O) 2 —N(R 2 )(R 2 ), —(C 1 -C 6 alkylene)-S(O) 2 —N(R 2 )(R 2 ), —C(O)—N(R 2 )(R 2 ), —N(R 2 )—C(O)R 1 , —(C 1 -C 6 alkylene)-N(R 2 )—C(O)R 1 , —NR 2 S(O) 2 R 1 , —P(O)(R 1 )(R 1 ), and —OR 1 ; wherein

each of aryl, heteroaryl, cycloalkyl, heterocyclyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 heteroalkyl is independently substituted with 0-5 occurrences of R a ; and

wherein at least one R A is halo;

each R B is independently halo;

each R 1 is independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl, wherein each of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl is independently substituted with 0-5 occurrences of R b ;

each R 2 is independently selected from hydrogen, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl; or 2 R 2 together with the nitrogen to which they are attached form a heterocyclyl ring substituted with 0-5 occurrences of R b ;

each R a and R b is independently selected from halo, cyano, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, C 1 -C 6 haloalkoxyl, —N(R″)(R″), —C(O)—N(R″)(R″), —N(R″)—C(O)R′, and —(C 1 -C 6 alkylene)-N(R″)—C(O)R′;

each R′ and R″ is independently selected from hydrogen, C 1 -C 6 alkyl, and C 1 -C 6 hydroxyalkyl;

m is 1, 2, 3, 4 or 5; and

n is 0, 1 or 2.

2. The method of claim 1 , wherein the compound is represented by Formula (Ia-1):

or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 , wherein each R a is independently selected from halo.

4. The method of claim 1 , wherein the compound is represented by Formula (Ib):

or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 , wherein one R A is halo and one R A is monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl.

6. The method of claim 1 , wherein the compound is selected from any one of the compounds in the table below:

Compound

Number

Structure

1

2

3

4

6

7

8

9

10

11

12

13

15

17

18

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the tumor is from a cancer, wherein the cancer is selected from non-small cell lung cancer, breast cancer, melanoma, low and high grade glioma, glioblastoma, pediatric astrocytoma, colorectal cancer, thyroid cancer, pancreatic cancer, biliary cancer, head and neck cancer, primary CNS tumors, cholangiocarcinoma, breast cancer, salivary gland cancer, sarcoma, and spitzoid neoplasms.

13. The method of claim 1 , wherein the tumor is characterized by the identification of an NTRK fusion.

14. The method of claim 13 , wherein the kinase domain of the NTRK fusion has a mutation.

15. The method of claim 14 , wherein the mutation is G595R.

16. The method of claim 12 , wherein the cancer is non-small cell lung cancer.

17. The method of claim 12 , wherein the cancer is thyroid cancer.

18. The method of claim 12 , wherein the cancer is pancreatic cancer.

19. The method of claim 12 , wherein the cancer is colorectal cancer.